| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||||
Net loss | ||||||||
-126,844 | -105,385 | -92,231 | -75,810 | -62,371 | -52,248 | 0 | 0 | 0 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation and amortization | ||||||||
4,923 | 3,775 | 2,673 | 1,674 | 1,105 | 1,019 | 0 | 0 | 0 |
Stock-based compensation | ||||||||
19,678 | 16,281 | 13,703 | 11,579 | 9,046 | 6,925 | 0 | 0 | 0 |
Accretion of discount on marketable securities | ||||||||
3,620 | 4,701 | 4,994 | 4,649 | 3,714 | 2,745 | 0 | 0 | 0 |
Amortization of right-of-use assets | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Loss from disposal of property and equipment, net | ||||||||
0 | - | - | - | - | -151 | 0 | 0 | 0 |
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |
Prepaid expenses and other current assets | ||||||||
2,150 | 1,596 | -124 | 1,505 | 3,945 | 2,245 | 0 | 0 | 0 |
Other assets | ||||||||
343 | 42 | 98 | 30 | -123 | -106 | 0 | 0 | 0 |
Accounts payable | ||||||||
2,604 | 152 | -73 | 435 | 657 | -809 | 0 | 0 | 0 |
Accrued liabilities and accrued clinical supply costs | ||||||||
17,967 | 9,210 | 13,335 | 11,535 | 5,407 | 4,743 | 0 | 0 | 0 |
Deferred revenue | ||||||||
-22,785 | -21,219 | -24,363 | -28,170 | -28,362 | 172,492 | 0 | 0 | 0 |
Deferred rent | ||||||||
- | -44 | -50 | -50 | -50 | -7 | 0 | 0 | 0 |
Lease liabilities | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Lease liabilities and other long-term liabilities | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |
Net cash used in operating activities | ||||||||
-108,055 | -99,308 | -88,135 | -81,631 | -80,627 | 127,464 | 0 | 0 | 0 |
Cash flows from investing activities: | ||||||||
Purchase of property and equipment | ||||||||
16,801 | 15,265 | 14,109 | 11,967 | 3,301 | 1,884 | 0 | 0 | 0 |
Purchase of marketable securities | ||||||||
465,283 | 529,609 | 488,357 | 543,354 | 560,565 | 472,235 | 0 | 0 | 0 |
Maturities of marketable securities | ||||||||
459,600 | 496,000 | 466,000 | 426,000 | 368,000 | 250,000 | 0 | 0 | 0 |
Net cash used in investing activities | ||||||||
-22,484 | -48,874 | -36,466 | -129,321 | -195,866 | -224,119 | 0 | 0 | 0 |
Cash flows from financing activities: | ||||||||
Proceeds from issuance of common stock upon initial public offering, net of issuance costs | ||||||||
225,423 | -170,128 | 172,310 | 172,032 | -168,403 | 1,904 | 0 | 0 | 0 |
Payment of convertible preferred stock issuance costs | ||||||||
- | - | - | - | - | - | - | - | 0 |
Proceeds from the exercise of options to purchase common stock | ||||||||
4,731 | 1,519 | 0 | 0 | 0 | - | - | - | - |
Net cash provided by financing activities | ||||||||
230,502 | 172,353 | 169,636 | 231,250 | 301,520 | 131,146 | 0 | 0 | 0 |
Net increase in cash, cash equivalents, and restricted cash | ||||||||
99,963 | 24,171 | 45,035 | 20,298 | 25,027 | 34,491 | 0 | 0 | 0 |
Non-cash investing and financing activities: | ||||||||
Property and equipment purchases included in accounts payable and accrued liabilities | ||||||||
2,578 | 3,471 | 3,938 | 3,134 | 1,255 | 293 | 0 | 0 | 0 |
Issuance costs for convertible preferred stock included in accounts payable | ||||||||
- | - | - | - | - | - | - | 0 | 0 |
Deferred offering costs in accounts payable and accrued liabilities | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Tenant improvements paid by landlord | ||||||||
- | 8,286 | 15,334 | 15,735 | 15,735 | 7,449 | 0 | 0 | 0 |